ENZN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 15:07):

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron...

Stats
Today's Volume	3 991.00
Average Volume	17 487.00
Market Cap	6.53M
EPS	$0 ( 2024-02-09 )
Next earnings date	( $0 ) 2024-05-06
Last Dividend	$0.120 ( 2019-09-30 )
Next Dividend	$0 ( N/A )
P/E	-8.80
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-16	Read Randolph C	Buy	84 550	Common Stock
2023-06-14	Read Randolph C	Buy	15 000	Common Stock
2022-06-09	Firestone Jaffrey Adam	Buy	0
2021-08-13	Couchman Jonathan	Sell	57 500	Common Stock, $0.01 par value
2021-08-13	Couchman Jonathan	Sell	50 000	Common Stock, $0.01 par value

INSIDER POWER
100.00
Last 86 transactions
Buy: 34 996 838 \| Sell: 942 903

Enzon Pharmaceuticals, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enzon Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.0185

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.0133

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00280

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00470

Financial Reports:

No articles found.

Enzon Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Enzon Pharmaceuticals, Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$2.00	2012-12-06
Last Dividend	$0.120	2019-09-30
Next Dividend	$0	N/A
Payout Date	2019-10-15
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$5.38	--
Avg. Dividend % Per Year	0.00%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-24)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for PNK

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PFBX	Ex Dividend Knight	2023-05-01	Annually	0.00%
GFASY	Ex Dividend Junior	2023-04-27	Semi-Annually	0.00%
ENBP	Ex Dividend Knight	2023-08-14	Quarterly	0.00%
CMTV	Ex Dividend Knight	2023-10-12	Quarterly	0.00%
TBTC	Ex Dividend Junior	2023-08-31	Sporadic	0.00%
QNBC	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
JUVF	Ex Dividend Knight	2023-08-16	Quarterly	0.00%
FMFG	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
CZFS	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
VABK	Ex Dividend Knight	2023-09-07	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	0.0288	1.200	9.04	10.00	[0 - 0.3]
returnOnEquityTTM	0.0390	1.500	-0.678	-1.017	[0.1 - 1]
payoutRatioTTM	0.929	-1.000	0.714	-0.714	[0 - 1]
currentRatioTTM	27.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	27.43	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	27.43	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.34	1.000	-0.246	-0.246	[3 - 30]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.23

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.21	1.000	9.68	0	[1 - 100]
returnOnEquityTTM	0.0390	2.50	-0.436	-1.017	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
payoutRatioTTM	0.929	1.500	0.714	-0.714	[0 - 1]
pegRatioTTM	-0.171	1.500	-4.47	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				2.04

Enzon Pharmaceuticals,

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.